Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Triovance Holding LLC currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is assigned to 1 distinct examiner, PRONZATI, GINA, who is also the busiest examiner with 1 pending action. The matter is currently being prosecuted within 1 distinct art unit.
With only that pending office action, the portfolio's immediate USPTO activity is highly focused. The involvement of 1 distinct art unit and 1 distinct examiner means that the prosecution strategy is entirely dependent on the interactions between PRONZATI, GINA and the applicant. This streamlined oversight in the Biotechnology & Pharmaceuticals area allows for a direct and singular focus on resolving the 1 pending office action.
Practitioners should focus on the specific requirements of PRONZATI, GINA to ensure a successful outcome for the matter. The concentration within that unit suggests a highly specialized technical focus. This singular prosecution path simplifies the management of the company's current patent efforts in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRONZATI, GINA | 1 | 65.9% | +48.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18683172 | A SKIN SUBSTITUTE COMPOSITION AND METHODS OF PRODUCING AND USING THE SAME | PRONZATI, GINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18683172 | A SKIN SUBSTITUTE COMPOSITION AND METHODS OF PRODUCING AND USING THE SAME | PRONZATI, GINA | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18683172 | A SKIN SUBSTITUTE COMPOSITION AND METHODS OF PRODUCING AND USING THE SAME | PRONZATI, GINA | 1633 | §102§103§112 | Non-Final OA | — | Pending | Feb 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTriovance Holding LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Gina Pronzati has the most, with 1 of Triovance Holding LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
